Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.45 |
| ▸ | UBE2M | P61081 | 5/20 | 0.44 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.44 |
| ▸ | TP53 | P04637 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 4/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.40 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5040128 | 0.92 | UBE2M (0.43) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL5040901 | 0.91 | THRB (0.46) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2800827 | 0.90 | LMNA (0.47) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2799416 | 0.89 | THRB (0.43) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL2799418 | 0.87 | THRB (0.38) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL5046584 | 0.86 | UBE2M (0.45) | THRBUBE2MDCUN1D1TP53LMNA | |
| SCHEMBL5040133 | 0.84 | KCNH2 (0.47) | THRBUBE2MDCUN1D1LMNAKCNH2 | |
| SCHEMBL12000224 | 0.83 | SLC2A1 (0.50) | TP53KCNH2MCHR1 | |
| Hydrochloric Acid SCHEMBL2796401 | 0.82 | SLC2A1 (0.51) | KCNH2MCHR1 | |
| SCHEMBL2800143 | 0.81 | UBE2M (0.39) | THRBUBE2MDCUN1D1TP53LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524738-B2 | Quinolinones and quinoxalinones as antibacterial composition | TOYAMA CHEMICAL CO., LTD. (JP) | 2013-09-03 | — | — | US | disclosed |
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-08-23 | — | — | US | disclosed |
| EP-2468743-A1 | Nitrogen-containing bicyclic compounds useful as antibacterial agents | Toyama Chemical Co., Ltd. (JP) | 2012-06-27 | — | — | EP | disclosed |
| EP-1900732-A1 | NOVEL NITROGENATED HETEROCYCLIC COMPOUND AND SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2008-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214990-A1 | QUINOLINONES AND QUINOXALINONES AS ANTIBACTERIAL COMPOSITION | NQO2, ASNS, NDUFS1 | THRB 4509/4885UBE2M 826/4885DCUN1D1 1635/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.